Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

inhaled insulin

This page shows the latest inhaled insulin news and features for those working in and with pharma, biotech and healthcare.

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi has handed back rights to inhaled insulin drug Afrezza to Mannkind, less than a year after its launch, after the diabetes treatment saw underwhelming sales. ... The disappointing performance of the drug also promoted other inhaled insulin

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    oral and inhaled insulin. ... I think the jury is out on inhaled insulin,” he says.

  • Sanofi's CEO search ends as Bayer's Brandicourt takes the job Sanofi's CEO search ends as Bayer's Brandicourt takes the job

    As Viehbacher's replacement Brandicourt faces a number of challenges, including the impending loss of patent protection for Sanofi big-selling diabetes therapy Lantus (insulin glargine).  . ... The company also has a number of key product launches

  • Sanofi launches inhaled insulin in US Sanofi launches inhaled insulin in US

    Partners with MannKind on only diabetes treatment of its kind.  . The device Afrezza will be distributed in. Sanofi has launched what will be the only inhaled insulin available to treat people ... Afrezza is the only product of its kind available in the

  • Sanofi cuts $925m deal for MannKind's inhaled insulin Sanofi cuts $925m deal for MannKind's inhaled insulin

    French company bolsters diabetes business with Afrezza collaboration. This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza. ... MannKind's search for a partner for its recently approved inhaled insulin therapy Afrezza has ended

  • Third time lucky as MannKind's inhaled insulin is approved Third time lucky as MannKind's inhaled insulin is approved

    US FDA backs new diabetes treatment Afrezza. An inhaled formulation of insulin for diabetes could be back on the market shortly after the US FDA approved MannKind's Affrezza. ... Afrezza is a short-acting inhaled insulin, a group which represents around

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with ... like peptide-1 (GLP-1), a hormone that works independently

  • Going the distance Going the distance

    The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... The drug-device combination delivers a dry formulation of human insulin via a small and portable inhaler, similar to those associated with

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).

  • Pharma deals during August 2014 Pharma deals during August 2014

    the leading pack diabetes drug companies, to ignore any lurking concerns caused by Pfizer's woeful experience with inhaled insulin (Exubera) and jump into this precarious game with MannKind. . ... The drug-device combination consists of a dry

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...

Quick links